MedTrace Logo

Midodrine in the Recovery Phase of Septic Shock

NCT02990546 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2024-01-11

No results posted yet for this study

Summary

The aim of this study is to investigate the role of oral midodrine in the recovery of septic shock. The investigators hypothesize that the oral drug can reduce central line days and ICU length of stay.

Conditions

  • Septic Shock

Interventions

DRUG

midodrine

Midodrine will be given to treatment arm as enteral medication

OTHER

Standard of Care

Patients in the control arm will receive standard of care for septic shock

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Robert M Jones, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-05-02
Completion
2018-05-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02990546 on ClinicalTrials.gov